









Markets
/
Stocks
/
nasdaq-fgen
/

FibroGen Inc

FGEN

11.000USD

0.000

Close 11/05, 16:00（ET）Quotes delayed by 15 min

44.48MMarket Cap

LossP/E TTM



FibroGen Inc

11.000

0.000

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of FibroGen Inc

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

FibroGen Inc's Score

Industry at a Glance

Industry Ranking

132 / 407

Overall Ranking

265 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

43.000

Target Price

+290.91%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FibroGen Inc Highlights

StrengthsRisks

FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.

Growing

The company is in a growing phase, with the latest annual income totaling USD 29.62M.

Undervalued

The company’s latest PE is -25.54, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.07M shares, decreasing 44.46% quarter-over-quarter.

Held by PRIMECAP Management

Star Investor PRIMECAP Management holds 89.70K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 6.41, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 1.35M, representing a year-over-year decrease of 97.34%, while its net profit experienced a year-over-year decrease of 51.09%.

Score

Industry at a Glance

Previous score

6.41

Change



Financials

3.77

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

5.57

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.47

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.23

Key Metrics

Free cash flow

No Data

FibroGen Inc's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 8.32, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -25.54, which is -99.99% below the recent high of -0.00 and -13.00% above the recent low of -28.86.

Score

Industry at a Glance

Previous score

8.32

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 132/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

The company’s current earnings forecast score is 7.00, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for FibroGen Inc is 43.00, with a high of 43.00 and a low of 43.00.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

43.000

Target Price

+290.91%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

FibroGen Inc

FGEN

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 6.70, which is higher than the Biotechnology & Medical Research industry's average of 6.49. Sideways: Currently, the stock price is trading between the resistance level at 11.67 and the support level at 10.31, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.63

Change

0.07

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(5)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.024

Neutral

RSI(14)

48.716

Neutral

STOCH(KDJ)(9,3,3)

58.157

Neutral

ATR(14)

0.472

Low Volatility

CCI(14)

46.905

Neutral

Williams %R

50.777

Neutral

TRIX(12,20)

-0.189

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

11.034

Sell

MA10

10.955

Buy

MA20

10.938

Buy

MA50

11.414

Sell

MA100

9.451

Buy

MA200

4.913

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-05

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 26.43%, representing a quarter-over-quarter decrease of 17.90%. The largest institutional shareholder is The Vanguard, holding a total of 178.04K shares, representing 4.40% of shares outstanding, with 24.51% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Armistice Capital LLC

336.00K

-1.18%

The Vanguard Group, Inc.

Star Investors

178.04K

-24.03%

Acadian Asset Management LLC

139.12K

-10.94%

PRIMECAP Management Company

Star Investors

89.70K

-40.06%

BlackRock Institutional Trust Company, N.A.

84.04K

-9.69%

Marshall Wace LLP

72.30K

-18.31%

Geode Capital Management, L.L.C.

44.04K

+1.98%

Hightower Advisors, LLC

39.75K

+145.65%

Wettig (Thane)

20.84K

-1.18%

Schoeneck (James A)

16.10K

+393.71%

Risk Assessment

Currency: USD Updated: 2025-11-05

The company’s current risk assessment score is 2.83, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.73. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.